Functional T cell reconstitution and human immunodeficiency virus-1- specific cell-mediated immunity during highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 180, Issue 1, 1999, Pages 76-86

  Pontesilli, Oscar ^a,d   Kerkhof Garde, Susana ^a   Notermans, Daan W ^b   Foudraine, Norbert A ^b   Roos, Marijke T L ^a   Klein, Michèl R ^a,d   Danner, Sven A ^b   Lange, Joep M A ^b   Miedema, Frank ^a,c  

^a CENTRAL LABORATORY   (Netherlands)

^b Natl AIDS Therapy Evaluation Centre   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RITONAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; VIREMIA;

ADULT; ANTI-HIV AGENTS; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; IMMUNITY, CELLULAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033051593     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314837     Document Type: Article

References (40)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissue to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-4.
4. Notermans DW, Jurriaans S, de Wolf F, et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 1998;12;167-73.
5. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
6. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
7. Pantaleo G. How immune-based intervention can change HIV therapy. Nature Med 1997;3:483-6.
8. Wei X, Ghosh SK, Taylor ME, et al. Viral dinamics in human immunodeficency virus type 1 infection. Nature 1995;373:117-22.
9. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocyte in HIV-1 infection. Nature 1995;373:123-6.
10. Kelleher AD, Carr AD, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
11. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
12. Pakker NG, Notermans DW, De Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998;4:208-14.
13. + T cell renewal in early HIV-1 infection: effect or highly active antiretroviral therapy. Nat Med 1998;4:794-801.
14. Van Griensven GJP, Tielman RAP, Goudsmit J, et al. Risk factors and prevalence of HIV antibodies in homosexual men in The Netherlands. Am J Epidemiol 1987;125:1048-57.
15. Foundraine NA, de Jong JJ, Weverling GJ, et al. An open randomized trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS 1998;12:1513-9.
16. Bloemena E, Roos MTL, van Heijst JLAM, Vossen JMJJ, Schellekens PTA. Whole-blood lymphocyte cultures. J Immunol Methods 1989;122:161-7.
17. Klein MR, Veenstra J, Holwerda AM, et al. Gag-specific immune responses after immunization with p17/p24: Ty virus-like particles in HIV type 1 seropositive individuals. AIDS Res Hum Retroviruses 1997;13:393-9.
18. Rautmann G, Kieny MP, Brandely R, et al. HIV-1 core proteins expressed from recombinant vaccinia viruses. AIDS Res Hum Retroviruses 1989;5:147-57.
19. Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, et al. Different patterns of HIV-1 specific cytotoxic T-lymphocyte activity after primary infection. AIDS 1995;9:421-6.
20. Van Baalen CA, Klein MR, Geretti AM, et al. Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: cytotoxic T-lymphocyte epitopes and precursors frequencies. AIDS 1993;7:781-6.
21. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-72.
22. Pontesilli O, Klein MR, Kerkhof-Garde SR, et al. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant Gag-specific response is associated with non-progressive infection. J Infect Dis 1996;178:1008-18.
23. Strijbosch LWG, Buurman WA, Does RJMM, Zinken PH, Groenewegen G. Limiting dilution assay: experimental design and statistical analysis. J Immunol Methods 1987;97:133-40.
24. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1993;4(RR-17):1-19.
25. Pontesilli O, Kerkhof-Garde S, Pakker NG, et al. Antigen-specific T lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Immunol Lett 1999;66:213-7.
26. + T-lymphocyte responses after gancyclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nature Med 1999;4:953-6.
27. + T-cell repopulation kinetics during highly active antiretroviral therapy. AIDS 1998;12:F235-40.
28. + repertoire during antiviral therapy. Nature Med 1998;4:215-21.
29. French MAII, Mallal S, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992;6:1293-7.
30. Clerici M, Stocks NI, Zajac RA, et al. Detection or three distinct patterns of T helper cell dysfunction in asymptomatic, Human Immunodeficiency Virus seropositive patients. J Clin Invest 1989;84:1892-99.
31. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand II, Autran B. Long-lasting recovery in CD4 T cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
32. Lasler SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988;141:2629-36.
33. Lederman MM, Connick E, Landay A, et al. Immunologic response associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group protocol 315. J Infect Dis 1998;178:70-9.
34. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 1998;280:72-7.
35. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
36. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73:797-800.
37. Dalod M, Harzie M, Pellegrin I, et al. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 1998;178:61-9.
38. + T cell responses associated with control of viremia. Science 1997;278:1447-50.
39. Plana M, Garcia F, Gallart T, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Lancet 1998;352:1194-5.
40. + T helper and a T-killer cell. Nature 1998;393:474-8.